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Abstract
Background: In meta-analyses supplementation with vitamin D appears to reduce incidence of fractures, and in
cross-sectional studies there is a positive association between serum 25-hydroxyvitamin D (25(OH)D) levels and
bone mineral density (BMD). However, the effect of supplementation with high doses of vitamin D on BMD is
more uncertain and could in theory have both positive and negative effects.
Methods: The study was a one year, double blind placebo-controlled intervention trial performed at the University
Hospital of North Norway. 421 subjects, 21 - 70 years old, were included and 312 completed the study. The
subjects were randomized to vitamin D3 40.000 IU per week (DD group), vitamin D3 20.000 IU per week (DP
group), or placebo (PP group). All subjects were given 500 mg calcium daily. Serum 25(OH)D, osteoprotegrin (OPG),
receptoractivator of nuclear factor-kappaB ligand (RANKL), and BMD at the lumbar spine and the hip were
measured before and at the end of the study.
Results: At baseline the mean serum 25(OH)D levels were 58 nmol/L (all subjects) and increased to 141 and 100
nmol/L in the DD and DP groups, respectively. After one year, no significant differences were found between the
three groups regarding change in BMD, serum OPG or RANKL.
Conclusions: Supplementation with high doses of vitamin D for one year does not appear to have a negative
effect on BMD in healthy subjects. In order to disclose a positive effect, subjects with low BMD and/or low serum
25(OH)D levels need to be studied.
Trial registration: The trial was registered at ClinicalTrials.gov (NCT00243256).
Background
A sufficient intake of vitamin D, or sun exposure for
production of vitamin D in the skin, is of vital impor-
tance for skeletal health, and patients with severe vita-
min D deficiency exhibit hypocalcemia and rickets or
osteomalacia [1].
The skeleton is constantly remodelled. This occurs in
small bone remodelling units where the balance between
bone resorption by the osteoclasts and bone matrix
s y n t h e s i sb yt h eo s t e o b l a s t sd e t e r m i n e st h ev o l u m ea n d
quality of the bone [2]. It has been known for many
years that the activity of the osteoclasts is influenced by
the osteoblast, which was clarified by the recent
discovery of the osteoprotegrin (OPG)/receptoractivator
of nuclear factor-kappaB (RANK)/RANK ligand
(RANKL) system [2-6]. Thus, the osteoblasts and the
bone marrow stromal cells produce RANKL which acti-
vates the osteoclasts by binding to its RANK receptor.
The osteoblasts also produce OPG which functions as a
decoy receptor and binds RANKL and thereby prevents
it from binding to RANK [2,7].
The classical effect of 1,25-dihydoxyvitamin D (1,25
(OH)2D), which is the active form of vitamin D, is to
increase the intestinal calcium absorption and thereby
have an indirect effect on bone formation [1]. In addition,
1,25(OH)2D has direct effects on bone, and receptors for
1,25(OH)2D (VDR) have been found in osteoclasts [8] as
well as in osteoblasts [9]. Traditionally, 1,25(OH)2Dh a s
been considered a bone-resorbing hormone. This was
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any medium, provided the original work is properly cited.based on its potent stimulation of bone resorption in tis-
sue cultures [10,11] which was further substantiated by
the finding that 1,25(OH)2D increased the RANKL expres-
sion [5,11]. However, active vitamin D metabolites have
also been reported to inhibit bone resorption [12] and
may therefore have a dual effect on bone formation [11].
From these in vitro experiments it is hard to predict
the effect of vitamin D supplementation on bone in
humans provided there is not a severe vitamin D defi-
ciency. If the effect is positive, one would expect that
supplementation with vitamin D would prevent osteo-
porotic fractures which was demonstrated in a recent
meta-analysis by Bischoff-Ferrari et al. [13]. A dose
dependency was also reported, and no effect was seen
with 400 IU per day. Similarly, in a large cross-sectional
study there was a positive relation between serum 25
(OH)D, which is the storage form of the vitamin and
the one used to evaluate a subject’s vitamin D status,
and bone mineral density (BMD) [14]. However, for
subjects above the age of 50 years, the BMD reached a
plateau at serum 25(OH)D levels of 90 - 100 nmol/L,
and thereafter appeared to decline. If this reflects a cau-
s a lr e l a t i o n ,v i t a m i nDg i v e ni nh i g hd o s e sm a yh a v ea
negative effect on bone. Given the focus on the need for
higher doses of vitamin D [15] this is an important issue
to settle, but so far, most intervention studies have used
vitamin D in doses of 800 IU per day or less [13].
We have recently performed a one year placebo-con-
trolled intervention study with vitamin D in doses of
20.000 IU and 40.000 IU per week with change in
weight as primary end point [16]. In addition, bone den-
sitometry was performed and serum OPG and RANKL
measured before and at the end of the study. This gave
us the opportunity to address the issue of skeletal effects
of high dose vitamin D supplementation.
Methods
The protocol has previously been described in detail
[16]. The subjects were recruited by advertisements in
local newspapers and from our outpatient clinic. The
subjects were initially screened at our outpatient clinic
at the Department of Internal Medicine at the Univer-
sity Hospital of North Norway. All potential participants
were told that they would be part of a weight loss study
assessing the effect of high doses of vitamin D on body
weight. Males and females 21 to 70 years old, with BMI
between 28.0 - 47.0 kg/m
2 were included. Subjects with
diabetes or a history of coronary infarction, angina pec-
toris, stroke, renal stone disease, or sarcoidosis were
excluded. Subjects with serum calcium > 2.55 mmol/L,
males with serum creatinine > 129 μmol/L and females
with serum creatinine > 104 μmol/L, and subjects using
bisphosphonates or oestrogen (for contraception or
replacement) were not included.
At baseline fasting blood samples were drawn and any
previous supplements with calcium and vitamin D
(including cod liver oil) were discontinued. All subjects
were given a daily supplement with 500 mg calcium
(Nycoplus Calcium®, Nycomed, Norway) throughout the
one year intervention period. The participants were
given oral information and written recommendations on
healthy diet and physical activity. The study was a ran-
domized, double blind clinical trial. Using block-rando-
mization, the subjects were randomized into one of
three groups, stratified by gender and smoking status:
one group was to take two capsules of vitamin D3 (20
000 IU cholecalciferol per capsule (Decristol®, Jena-
pharm, Jena, Germany)) per week; one group one cap-
sule of vitamin D3 and one placebo capsule per week;
and one group two placebo capsules per week. The sub-
jects were supplied with new medication every third
month. Unused calcium tablets and capsules were
returned and counted. The subjects were classified as
current smokers or current non-smokers. Non-fasting
blood samples for serum calcium analysis were drawn
a f t e r3 ,6 ,a n d9m o n t h st od i s c l o s ed e v e l o p m e n to f
hypercalcemia.
Measurements
Height and weight were measured wearing light clothing
and no shoes. Serum calcium and parathyroid hormone
(PTH) were measured as previously described [17].
Serum levels of 25-hydroxyvitamin D (25(OH)D) were
measured by radioimmunoassay (DiaSorin, Stillwater,
MN, USA). This assay measures both 25(OH)D3 and 25
(OH)D2, and the intra- and total assay coefficients of
variation (CVs) are 6% and 14%, respectively [18]. BMD
was determined by anterior-posterior dual-energy X-ray
absorptiometry (DEXA) scans at the lumbar spine and
hip according to the manufacturer (GE Lunar Prodigy,
LUNAR Corporation, Madison, WI, USA). The mean of
L2-L4 and the mean of the right and left total hip values
were used in the analyses (CV 3.6%). Serum OPG was
measured as previously described with an intra-assay
CV of 3.2% and inter-assay CV of 11.1% [19]. The con-
centration of free RANKL was measured by a new,
highly sensitive ELISA assay for free RANKL with a
detection limit of 0.02 pmol/l, an intra-assay CV of 9.6%
and an inter-assay CV of 15.3% (ampli sRANKL human,
Biomedica, Vienna, Austria). The analysis was per-
formed according to the manufacturer’s instruction. The
analyses of serum OPG and RANKL were performed on
coded samples without knowledge of clinical status by
the person performing the assays. All samples were ana-
lyzed in duplicate and the mean value is used in this
report. OPG and RANKL were measured in baseline
sera in all subjects who completed the study and in sera
from the end of the study in a random sample of sub-
jects in the DD and PP groups as appear in the tables.
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Normal distribution was evaluated with visual inspection
of histograms with normal curve, and determination of
skewness and kurtosis. All dependent variables except
serum OPG and RANKL were considered normally dis-
tributed at baseline. After log transformation OPG
attained normal distribution and was used as such when
parametric statistics were applied. Because of several 0-
values (not detectable) RANKL could not be log trans-
formed and therefore was evaluated with non-para-
metric statistics. The delta values for OPG and RANKL
were also not normally distributed and could not be log
transformed because of several 0-values, and were there-
fore evaluated with non-parametric statistics. The other
delta values were normally distributed. A multiple linear
regression model with age, gender, BMI, smoking status,
serum 25(OH)D, serum PTH and serum calcium as cov-
ariates was used to evaluate individual predictor of BMD
L2-L4, BMD total hip and serum OPG. Correlations
were evaluated with Pearson’s or Spearman’sc o r r e l a t i o n
coefficients as appropriate.
The intervention study was analysed per protocol.
Comparisons between the groups at baseline and
between their delta values (value at end of the study
minus value at baseline) were performed with ANOVA,
the Kruskall Wallis test or the Chi-square test. The Bon-
ferroni correction was used where multiple comparisons
were performed. Unless otherwise stated, data are
expressed as mean ± SD. All tests were done two-sided,
and P-value < 0.05 was considered statistically signifi-
cant. The Statistical Package for Social Sciences version
15.0 was used for all statistical analyses (SPSS Inc., Chi-
cago, Ill., USA).
The power calculation was performed according to the
primary end point (weight loss) to disclose a clinically
significant difference of 6 kg with or without vitamin D
supplementation [16].
Ethics
The study was approved by the Regional Ethics Com-
mittee. All participants gave written informed consent
prior to the study.
Results
Baseline
The inclusion period started in November 2005 and the
last person was included in October 2006. Of 626 sub-
jects initially screened by telephone interview, 421 (156
men and 265 women) met the inclusion criteria and had
complete datasets (Figure 1). The baseline characteristics
of these subjects are shown in Table 1. Among the
women, 114 were postmenopausal. The age distribution
among the men and women are shown in Figure 2. The
mean serum 25(OH)D levels was 57.7 ± 20.7 nmol/L
and the distribution is shown in Figure 3. As expected
there were a number of significant univariate correla-
tions between the parameters measured (Table 2). How-
ever, after adjusting for confounders in the multiple
linear regression model onlyaf e wo ft h e s er e l a t i o n s
remained significant. In particular, serum PTH remained
as a significant and negative predictor of BMD both for
L2-L4 and the hip, and female gender and high age
were associated with Lg OPG (Table 3). Serum OPG
was negatively correlated with BMD L2-L4 and BMD at
the hip, but not after adjusting for the other covariates
(data not shown). Serum RANKL was below the detec-
tion limit in 141 of the 336 subjects with RANKL mea-
surement at baseline, and no association was found with
any of the other parameters measured.
Intervention study
One hundred and forty-seven, 132 and 142 subjects
were randomized to the DD, DP and PP groups, respec-
tively. 110 subjects in the DD group, 97 subjects in the
DP group, and 105 subjects in the PP group completed
the study (Figure 1). The reasons for the dropouts (37
subjects in the DD group, 35 subjects in the DP group
and 37 subjects in the PP group) have previously been
described in detail [16]. However, most of those who
dropped out withdrew their consent for participation
without stating a specific reason. The compliance rate in
the DD, DP and PP groups were for the vitamin D/pla-
cebo capsules 95%, 96%, 96%, and for the calcium
tablets 82%, 84%, and 83%, respectively. At baseline,
those in the DP group had BMI 1.5 kg/m
2 lower than
those in the PP group (P < 0.05). Apart from this differ-
ence, the DD, DP and PP groups were similar (Table 4).
At the end of the study serum 25(OH)D levels were
140.9 ± 34.7 nmol/L, 99.7 ± 20.3 nmol/L, and 57.9 ±
20.4 nmol/L in the DD, DP and PP groups respectively.
T h e r ew a sah i g h l ys i g n i f i c a n tp o s i t i v ec o r r e l a t i o n
between baseline and 12 months serum 25(OH)D in
both the DD and DP groups (r = 0.40 and r = 0.69,
respectively (P < 0.001)), and a significant negative cor-
relation between baseline and delta serum 25(OH)D (r =
- 0.57 and r = - 0.49, respectively (P < 0.001)). Accord-
ingly, in those given vitamin D, those with the lowest
baseline serum 25(OH)D levels had the highest increase
i ns e r u m2 5 ( O H ) D ,b u tn o th i g he n o u g ht oe v e no u t
the differences seen at baseline. There was a significant
decrease in the serum PTH levels in the DD and DP
groups, but no significant changes in weight or serum
calcium. The three groups did not differ significantly in
delta values for BMD L2-L4, BMD hip, serum OPG or
serum RANKL (Table 4), not even when the DD and
DP groups were combined to one vitamin D group and
compared with the PP group, or when only subjects
with low serum 25(OH)D values (< the 25
th percentile
(< 45.0 nmol/L)) were evaluated separately (data not
shown).
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and one subject in the DD group had a decrease of
11.5% in BMD L2-L4. Apart from these two subjects
none had an increment or a decrement outside the
“least significant change” (2.8 × CV) regarding the bone
densitometry.
Among the 66 women in the DD group, 58 women in
the DP group, and 64 women in the PP group, 29, 28
and 35 women, respectively, were postmenopausal.
However, the delta values for these women did not dif-
fer significantly between the DD, DP and PP groups,
being for BMD L2-L4 0.004 ± 0.03 g/cm
2, - 0.006 ±
0.035 g/cm
2, and - 0.006 ± 0.035 g/cm
2, respectively;
and for BMD hip 0.003 ± 0.013 g/cm
2, 0.008 ± 0.015 g/
cm
2, and 0.003 ± 0.014 g/cm
2, respectively.
Adverse events
As previously described in detail [16], no serious adverse
events were seen and there were no significant differences
626 subjects screened by 
telephone interview 
 
545 invited to screening 
 
73 subjects not eligible 
 
472 invited to baseline 
 
51 subjects not included; 
 
421 randomized and included 
147 randomized to DD  132 randomized to DP  142 randomized to PP 
110 randomized to DD 
completed the study 
97 randomized to DP 
completed the study 
105 randomized to PP 
completed the study 
37 subjects lost to 
follow-up or 
discontinued 
intervention 
35 subjects lost to 
follow-up or 
discontinued 
intervention 
37 subjects lost to 
follow-up or 
discontinued 
intervention 
 
81 subjects not eligible; 
Figure 1 Study consort diagram.
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Two subjects were diagnosed as having primary hyperpar-
athyroidism during the study, and one had an increase in
serum calcium to 2.62 mmol/L, and all three were
excluded from the study. Four subjects had transient
increases in serum calcium > 2.59 mmol/L and remained
in the study.
Discussion
In the present study we found no significant associations
for serum 25(OH)D with BMD, serum OPG or serum
RANKL at baseline after adjustment for confounders,
nor did vitamin D supplementation for one year differ
form placebo regarding change in BMD, serum OPG or
serum RANKL. On the other hand, a high serum PTH
level was associated with reduced BMD in the spine and
the hip.
Regarding the negative association between PTH and
B M Dt h i si si nl i n ew i t hp r e v i o u sp u b l i c a t i o n sf r o m
large cross-sectional studies [20,21], whereas the lack of
association between 25(OH)D and BMD differs from the
report by Bischoff-Ferrari et al. [14], and was most likely
due to selection and number of subjects in our study.
Apart from the expected significant increase in serum
OPG with age and the higher levels in females [22],
OPG or RANKL were not significantly associated with
any of the other variables included in the study. In parti-
cular, there was after adjustment for confounders no
significant relation between OPG and BMD, which is
Table 1 Baseline characteristics of all the 421 subjects
included in the study
Males (%) 37.1
Age (years) 47.1 ± 11.4
BMI (kg/m
2) 34.8 ± 3.9
Smokers (%) 22.3
BMD L2-L4 (g/cm
2) 1.256 ± 0.163
BMD total hip (g/cm
2) 1.096 ± 0.136
OPG (pg/ml)
1 1970 ± 672
RANKL (pg/ml)
1 0.08 ± 0.17
Serum 25(OH)D (nmol/L) 57.7 ± 20.7
Serum PTH (pmol/L) 5.41 ± 1.87
Serum calcium (mmol/L) 2.31 ± 0.11
1N = 336
Table 2 Pearson’s correlation coefficient between baseline values in the 421 subjects
Age
(years)
BMI
(kg/m
2)
BMD L2-L4
(g/cm
2)
BMD total
hip (g/cm
2)
Lg OPG
(pg/ml)
1
RANKL
(pg/ml)
1
Serum
25(OH)D
(nmol/L)
Serum
PTH
(pmol/L)
Age (years)
BMI (kg/m
2) - 0.15
†
BMD L2-L4 (g/cm
2) - 0.21
‡ 0.04
BMD total hip (g/cm
2) - 0.36
‡ 0.24
‡ 0.64
‡
Lg OPG (pg/ml)
1 0.38
‡ - 0.04 - 0.13* - 0.15
†
RANKL (pg/ml)
1 - 0.06
2 - 0.08
2 - 0.01
2 - 0.03
2 - 0.02
2
Serum 25(OH)D (nmol/L) 0.31
‡ - 0.16
† 0.04 - 0.07 0.20
‡ 0.07
2
Serum PTH (pmol/L) 0.08 0.19
‡ - 0.18
‡ - 0.11* 0.01 - 0.05
2 - 0.26
‡
Serum calcium (mmol/L) 0.30 0.02 0.02 0.05 0.09 - 0.08
2 0.06 - 0.10*
*P <0 . 0 5 ;
†P <0 . 0 1 ;
‡P > 0.001
1N=3 3 6
2Spearman’s correlation coefficient
Table 3 Baseline relations evaluated with multiple linear regression in the 421 subjects. Values are standardized
b-coefficients.
Dependent variables R
2 Independent variables in the model
Age
(years)
BMI
(kg/m
2)
Gender
1 Smoking
status
2
Serum
25(OH)D
(nmol/L)
Serum
PTH
(pmol/L)
Serum
calcium
(mmol/L)
BMD L2-L4 (g/cm
2) 0.10 - 0.22
‡ 0.06 - 0.13
† 0.07 0.06 - 0.17
‡ 0.01
BMD total hip (g/cm
2) 0.25 - 0.34
‡ 0.24
‡ - 0.25
‡ 0.05 0.03 - 0.13
† 0.04
Lg OPG (pg/ml)
3 0.17 0.36
‡ 0.04 0.11* 0.07 0.07 0.01 0.09
*P <0 . 0 5 ;
†P <0 . 0 1 ;
‡P > 0.001
1Males = 1, females = 2;
2Smokers = 1, non-smokers = 2;
3N = 336
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including 1630 subjects [23].
In the intervention study, our vitamin D doses of
20.000 IU and 40.000 IU per week were substantially
higher than those usually given in osteoporosis studies.
This resulted in serum 25(OH)D levels in the high phy-
siological range [24], but no significant change in BMD
was found. However, a positive effect of vitamin D on
B M Dc a n n o tb er u l e do u tf r o mo u rs t u d ya sm o s to f
the subjects had normal BMD at baseline, the study
only lasted 12 months, and an increase in BMD would
therefore be hard to disclose. On the other hand, sup-
plementation with vitamin D could in theory also have a
negative effect on BMD as the production of 1,25
(OH)2D from 25(OH)D is substrate dependent [25] and
1,25(OH)2D may induce osteoclastogenesis [5,11]. Our
result is therefore of importance as it indicates that high
doses of vitamin D, at least when given for a short per-
iod of time to healthy subjects, do not have serious
adverse effects on bone. However, it must be empha-
sised that a direct and negative effect of vitamin D
could be masked in our study by the concomitant fall in
serum PTH, as a fall in serum PTH may have a benefi-
cial effect on BMD [21,26].
Although 1,25(OH)2D has been demonstrated in in-
vitro studies to increase RANKL expression [5] and
reduce the OPG expression [9], supplementation with
vitamin D in our study did not significantly affect their
serum levels. In other studies where serum OPG and
RANKL have been measured after therapy, the results
have varied [27]. Thus, both serum OPG and RANKL
have been found to decrease after treatment with oes-
trogen in postmenopausal women in one study [28],
whereas serum OPG but not RANKL increased after
oral contraceptives in another study [29]. No effect on
OPG by bisphosphonate therapy has been reported in
subjects with osteoporosis or rheumatoid arthritis
[30,31], whereas a decrease in OPG after bisphospho-
nates has been found in subjects with Paget’sd i s e a s e
[30]. Most likely oestrogen, as well as bisphosphonates,
influence the production of OPG and RANKL as
demonstrated in in-vitro studies [32,33]. Therefore, the
lack of corresponding changes in serum levels indicate
that the circulating levels of OPG and RANKL do not
reflect the concentrations in the local tissues [27].
Our study has several limitations, and the results
should be evaluated with caution. Thus, the effect of
vitamin D on BMD, serum OPG and RANKL were only
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Figure 2 Age distribution in the 156 males and 265 females at baseline.
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not vitamin D deficient, and serum 1,25(OH)2D was not
measured. All subjects were given calcium supplementa-
tion and the results should therefore be interpreted as
vitamin D plus calcium versus calcium alone. On the
other hand, our study is of importance as we used high
vitamin D doses resulting in serum 25(OH)D levels in
the high physiological range.
Conclusion
Supplementation with high doses of vitamin D for one
year did not have a negative effect on BMD at the spine
or hip in healthy overweight or obese subjects, and a
relation between serum levels of vitamin D and OPG
and RANKL could not be demonstrated.
However, in order to disclose a positive effect
on BMD, subjects with low BMD and/or low serum
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Figure 3 Distribution of serum 25(OH)D in the 421 subjects at baseline.
Table 4 Baseline and delta values in those who completed the study
Baseline values Delta values (value at end of study minus
baseline)
DD group DP group PP group DD group DP group PP group
N 110 97 105
Males (%) 40.0 40.2 39.0
Age (years) 47.3 ± 11.1 47.7 ± 11.6 50.8 ± 10.7
BMI (kg/m
2) 34.4 ± 3.9 33.7 ± 3.5* 35.2 ± 3.9 0.01 ± 1.33 0.13 ± 1.10 0.09 ± 1.35
Smokers (%) 20.9 20.6 17.1
BMD L2-L4 (g/cm
2) 1.270 ± 0.155 1.235 ± 0.161 1.251 ± 0.170 0.008 ± 0.036 0.008 ± 0.039 0.007 ± 0.042
BMD total hip (g/cm
2) 1.107 ± 0.133 1.067 ± 0.128 1.092 ± 0.130 0.008 ± 0.014 0.011 ± 0.014 0.009 ± 0.017
OPG (pg/ml) 1875 ± 509 1961 ± 600 2092 ± 650 56 ± 306
1 - 34 ± 472
2
RANKL (pg/ml) 0.09 ± 0.15 0.10 ± 0.27 0.05 ± 0.10 - 0.01 ± 0.10
1 0.00 ± 0.06
2
Serum 25(OH)D (nmol/L) 61.3 ± 20.7 58.3 ± 21.2 60.1 ± 22.3 79.9 ± 31.3
† 41.7 ± 22.8
† - 2.2 ± 16.8
Serum PTH (pmol/L) 5.1 ± 1.6 5.4 ± 1.8 5.7 ± 1.7 - 0.9 ± 1.5
† - 0.7 ± 1.4* - 0.2 ± 1.6
Serum calcium (mmol/L) 2.30 ± 0.11 2.32 ± 0.11 2.31 ± 0.10 - 0.01 ± 0.12 - 0.02 ± 0.12 - 0.01 ± 0.11
*P <0 . 0 5 ;
†P < 0.001 versus delta values in the PP grooup
1N = 76;
2N=8 1
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of time.
Acknowledgements
The present study was supported by a grant from The Northern Norway
Regional Health Authority. The superb assistance by the staff at the Clinical
Research Unit and by Inger Myrnes and Astrid Lindvall at the Department of
Medical Biochemistry, University Hospital of North Norway, is gratefully
acknowledged. We are grateful for the generous supply of calcium tablets
from Nycomed Norway.
Author details
1Institute of Clinical Medicine, University of Tromsø, and Medical Clinic,
University Hospital of North Norway, Tromsø, Norway.
2Department of
Ophthalmology and Neurosurgery, Division of Ophthalmology, University
Hospital of North Norway, Tromsø, Norway.
3Hormone Laboratory, Aker
University Hospital, Oslo, Norway.
4Department of Medical Biochemistry,
University Hospital of North Norway, and Institute of Medical Biology,
University of Tromsø, Tromsø, Norway.
5Center for Atherothrombotic
Research in Tromsø (CART), Institute of Clinical Medicine, University of
Tromsø, Norway.
Authors’ contributions
RJ: study design, data gathering, preparation manuscript. MS: data gathering,
preparation manuscript. PAT: vitamin D analyses, preparation manuscript. YF:
biochemical analyses, preparation manuscript. JBH: OPG and RANKL analyses,
preparation manuscript. GG: statistical analyses, preparation manuscript. All
authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 12 September 2009
Accepted: 7 January 2010 Published: 7 January 2010
References
1. DeLuca HF: Overview of general physiologic features and functions of
vitamin D. Am J Clin Nutr 2004, 80:1689S-1696S.
2. Vega D, Maalouf NM, Sakhaee K: Clinical Review: the role of receptor
activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin:
clinical implications. J Clin Endocrinol Metab 2007, 92:4514-4521.
3. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K:
Isolation of a novel cytokine from human fibroblasts that specifically
inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997, 234:137-
142.
4. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R,
Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M,
Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N,
Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S,
Van G, Tarpley J, Derby P, Lee R, Boyle WJ: Osteoprotegerin: a novel
secreted protein involved in the regulation of bone density. Cell 1997,
89:309-319.
5. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S,
Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K,
Udagawa N, Takahashi N, Suda T: Osteoclast differentiation factor is a
ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is
identical to TRANCE/RANKL. Proc Natl Acad Sci 1998, 95:3597-3602.
6. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R,
Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E,
Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G,
Guo J, Delaney J, Boyle WJ: Osteoprotegerin ligand is a cytokine that
regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
7. Boyce BF, Xing L: Functions of RANKL/RANK/OPG in bone modeling and
remodeling. Arch Biochem Biophys 2008, 473:139-146.
8. Takasu H, Sugita A, Uchiyama Y, Katagiri N, Okazaki M, Ogata E, Ikeda K: c-
Fos protein as a target of anti-osteoclastogenic action of vitamin D, and
synthesis of new analogs. J Clin Invest 2006, 116:528-535.
9. Baldock PA, Thomas GP, Hodge JM, Baker SU, Dressel U, O’Loughlin PD,
Nicholson GC, Briffa KH, Eisman JA, Gardiner EM: Vitamin D action and
regulation of bone remodeling: suppression of osteoclastogenesis by
the mature osteoblast. J Bone Miner Res 2006, 21:1618-1626.
10. Raisz LG, Trummel CL, Holick MF, DeLuca HF: 1,25-
dihydroxycholecalciferol: a potent stimulator of bone resorption in
tissue culture. Science 1972, 175:768-769.
11. Ikeda K: Vitamin D, osteoclastogenesis and bone resorption: from
mechanistic insight to the development of new analogs. Endocr J 2007,
54:1-6.
12. Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K,
Ikeda K, Nakamura T, Matsumoto T, Ogata E: Alfacalcidol inhibits bone
resorption and stimulates formation in an ovariectomized rat model of
osteoporosis: distinct actions from estrogen. J Bone Miner Res 2000,
15:770-779.
13. Bischoff-Ferrari HA, Willett WC, Wong JB, Stuck AE, Staehelin HB, Orav EJ,
Thoma A, Kiel DP, Henschkowski J: Prevention of nonvertebral fractures
with oral vitamin D and dose dependency: a meta-analysis of
randomized controlled trials. Arch Intern Med 2009, 169:551-561.
14. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B: Positive
association between 25-hydroxy vitamin D levels and bone mineral
density: a population-based study of younger and older adults. Am J
Med 2004, 116:634-639.
15. Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF,
Heaney RP, Holick MF, Hollis BW, Lamberg-Allardt C, McGrath JJ,
Norman AW, Scragg R, Whiting SJ, Willett WC, Zittermann A: The urgent
need to recommend an intake of vitamin D that is effective. Am J Clin
Nutr 2007, 85:649-650.
16. Sneve M, Figenschau Y, Jorde R: Supplementation with cholecalciferol
does not result in weight reduction in overweight and obese subjects.
Eur J Endocrinol 2008, 159:675-684.
17. Kamycheva E, Jorde R, Figenschau Y, Haug E: Insulin sensitivity in subjects
with secondary hyperparathyroidism and the effect of a low serum 25-
hydroxyvitamin D level on insulin sensitivity. J Endocrinol Invest 2007,
30:126-132.
18. Osmancevic A, Nilsen LT, Landin-Wilhelmsen K, Søyland E, Abusdal
Torjesen P, Hagve TA, Nenseter MS, Krogstad AL: Effect of climate therapy
at Gran Canaria on vitamin D production, blood glucose and lipids in
patients with psoriasis. J Eur Acad Dermatol Venereol 2009, 23:1133-1140.
19. Vik A, Mathiesen EB, Notø AT, Sveinbjørnsson B, Brox J, Hansen JB: Serum
osteoprotegerin is inversely associated with carotid plaque echogenicity
in humans. Atherosclerosis 2007, 191:128-134.
20. von Mühlen D, Greendale G, Garland C, Wan L, Barrett-Connor E: Vitamin
D, parathyroid hormone levels and bone mineral density in community-
dwelling older women: The Rancho Bernardo Study. Osteoporosis
International 2005, 16:1721-1726.
21. Sneve M, Emaus N, Joakimsen RM, Jorde R: The association between
serum parathyroid hormone and bone mineral density, and the impact
of smoking: the Tromso Study. Eur J Endocrinol 2008, 158:401-409.
22. Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R,
Austrian Study Group on Normative Values of Bone Metabolism: Serum
levels of osteoprotegerin increase with age in a healthy adult
population. Bone 2003, 32:681-686.
23. Indridason OS, Franzson L, Sigurdsson G: Serum osteoprotegerin and its
relationship with bone mineral density and markers of bone turnover.
Osteoporos Int 2005, 16:417-423.
24. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B:
Estimation of optimal serum concentrations of 25-hydroxyvitamin D for
multiple health outcomes. Am J Clin Nutr 2006, 84:18-28.
25. Zittermann A: Vitamin D and disease prevention with special reference
to cardiovascular disease. Progress in Biophysics and Molecular Biology 2006,
92:39-48.
26. Lee SK, Lorenzo JA: Parathyroid hormone stimulates TRANCE and inhibits
osteoprotegerin messenger ribonucleic acid expression in murine bone
marrow cultures: correlation with osteoclast-like cell formation.
Endocrinology 1999, 140:3552-3561.
27. Rogers A, Eastell R: Circulating osteoprotegerin and receptor activator for
nuclear factor kappaB ligand: clinical utility in metabolic bone disease
assessment. J Clin Endocrinol Metab 2005, 90:6323-6331.
28. Crisafulli A, Altavilla D, Squadrito G, Romeo A, Adamo EB, Marini R,
Inferrera MA, Marini H, Bitto A, D’Anna R, Corrado F, Bartolone S, Frisina N,
Squadrito F: Effects of the phytoestrogen genistein on the circulating
soluble receptor activator of nuclear factor kappaB ligand-
Jorde et al. Nutrition Journal 2010, 9:1
http://www.nutritionj.com/content/9/1/1
Page 8 of 9osteoprotegerin system in early postmenopausal women. J Clin
Endocrinol Metab 2004, 89:188-192.
29. Hofbauer LC, Schoppet M, Schüller P, Viereck V, Christ M: Effects of oral
contraceptives on circulating osteoprotegerin and soluble RANK ligand
serum levels in healthy young women. Clin Endocrinol 2004, 60:214-219.
30. Alvarez L, Peris P, Guañabens N, Vidal S, Ros I, Pons F, Filella X, Monegal A,
Muñoz-Gomez J, Ballesta AM: Serum osteoprotegerin and its ligand in
Paget’s disease of bone: relationship to disease activity and effect of
treatment with bisphosphonates. Arthritis Rheum 2003, 48:824-828.
31. Valleala H, Mandelin J, Laasonen L, Koivula MK, Risteli J, Konttinen YT: Effect
of cyclical intermittent etidronate therapy on circulating osteoprotegerin
levels in patients with rheumatoid arthritis. Eur J Endocrinol 2003,
148:527-530.
32. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL:
Estrogen stimulates gene expression and protein production of
osteoprotegerin in human osteoblastic cells. Endocrinology 1999,
140:4367-4370.
33. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Gründker C,
Hofbauer LC: Bisphosphonates pamidronate and zoledronic acid
stimulate osteoprotegerin production by primary human osteoblasts.
Biochem Biophys Res Commun 2002, 291:680-686.
doi:10.1186/1475-2891-9-1
Cite this article as: Jorde et al.: No significant effect on bone mineral
density by high doses of vitamin D3 given to overweight subjects for
one year. Nutrition Journal 2010 9:1.
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Jorde et al. Nutrition Journal 2010, 9:1
http://www.nutritionj.com/content/9/1/1
Page 9 of 9